In a pre-seed fundraising round headed by Speciale Invest, Peptris Technologies, an artificial intelligence-powered drug discovery firm based in Bengaluru, secured $1 million.
The funds will be used by the business to intensify efforts in the pharmaceutical development and discovery space to advance AI-driven solutions, with a particular emphasis on creating new treatments for targets that are difficult to hit, especially in the areas of rare diseases, inflammation, and cancer.
“The current funding will help us accelerate our AI-powered discovery programs and create a robust pipeline of potential drug candidates,” said Narayanan Venkatasubramanian, cofounder and CEO of Peptris.
Peptris has developed a variety of AI models to forecast several factors that are necessary for a novel chemical to be taken into consideration as a possible therapeutic option.
All of these models are controlled by an automated workflow that both generates denovo versions of compounds that are anticipated to be unique, potent, safe, selective, and clinically active, as well as prunes enormous databases of buyable compounds to find possible hits.
Commenting on the investment, Vishesh Rajaram, managing partner, Speciale Invest, said, “Peptris’ groundbreaking work in AI-driven drug discovery aligns perfectly with Speciale’s investment strategy. We hope this partnership will help leverage India’s pharmaceutical expertise and computational talents, making a significant impact globally.”
Peptris is a preclinical drug development firm driven by artificial intelligence that focuses on uncommon diseases, inflammation, and cancer.